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Abstract  
BACKGROUND: The aim of this study is estimation of pharmacokinetic parameters: Cmax, tmax, t1/2, 
AUC0-t and AUC0-∞ with the two-way analysis of variance, single observation (ANOVA) for two 
preparations containing acyclovir.  
OBJECTIVE: In order to evaluate pharmacokinetic study of acyclovir, method for quantitative 
determination of acyclovir in human plasma should be simple, rapid and reproducible. Therefore, 
the method is developed, validated and applied for analysis of acyclovir in plasma samples 
obtained from healthy volunteers. 
MATERIAL AND METHODS: High performance liquid chromatographic (HPLC) method with UV-
detection for the determination of acyclovir in human plasma is presented. This method involves 
protein precipitation with 20 % (V/V) perchloric acid. The chromatographic separation was 
accomplished on a reversed phase C8 column with a mobile phase composed of 0.1 % (V/V) 
triethylamine in water (pH 2.5). No internal standard is required. UV detection was set at 255 nm. 
The method was successfully applied for the evaluation of pharmacokinetic profiles of acyclovir 
tablets in 24 healthy volunteers. 
RESULTS: The validation results shows that proposed method is rugged, precise (RSDs for intra- 
and inter-day precision ranged from 1.02 to 8.37 %) and accurate (relative errors are less than 6.66 
%). The calibration curve was linear in the concentration range of 0.1-2.0 µg/ml and the limit of 
quantification was 0.1 µg/ml. The Cmax, tmax and AUCs for the two products were not statistically 
different (p>0.05), suggesting that the plasma profiles generated by Zovirax were comparable to 
those produced by acyclovir manufactured by Jaka 80 company. 
CONCLUSION: Good precision, accuracy, simplicity, sensitivity and shorter time of analysis of the 
method makes it particularly useful for processing of multiple samples in a limited period of time for 
pharmacokinetic study of acyclovir. 
 
 
 
 
Introduction 
 
Acyclovir is considered the drug of choice for 
the treatment of initial and recurrent mucosal or 
cutaneous herpes simplex (HSV-1 and HSV-2) 
infections in immunocompromised adults and children, 
for the treatment of severe first episodes of genital 
herpes infections in immunocompetent patients; for 
the treatment of herpes simplex encephalitis, for the 
treatment of neonatal herpes infections and for the 
treatment of varicella-zoster infections in 
immunocompromised adults and children [1]. 
A number of assay methods have been 
reported for determination of acyclovir in biological 
fluids using capillary electrophoresis [2] or liquid 
chromatographic methods with pulsed amperometric 
detection [3], tandem mass spectrometry [4], 
fluorescence detection [5-7] or ultraviolet detection [8-
15]. In the published methods, liquid-liquid extraction 
with acetonitrile or mixture of isopropyl alcohol and 
dichloromethane as solvent has been used for sample 
preparation [4, 8, 9]. The disadvantage of these 
methods employing liquid-liquid extraction (with grate 
chemical consumption) of acyclovir from biological 
fluids is that they involve several steps yielding poor 
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separation from the serum endogenous interferences. 
In order to improve purification of biological samples 
Fernandez et al. proposed a solid-phase extraction 
method [10]. Solid-phase extraction technique is a 
fairly expensive procedure and suffers from sorbent 
drying between washing intervals which may result in 
cracking of the packing material. Sometimes, using 
liquid-liquid or solid-phase extraction there are 
problems in the dissolution of the residue after 
extraction and evaporation of organic layer under a 
gentle stream of nitrogen. All these methods are time 
consuming (usually up to 1 h) regarding to multiple 
steps of extraction, drying etc. Other authors 
proposed protein precipitation method for sample 
preparation with 20 % trichloroacetic acid or 7 % 
perchloric acid [5-7, 11-15]. Emami et al. reported that 
protein precipitation method can deteriorate the 
chromatographic column due to either high acidity or 
inadequate precipitation of protein contents in 
samples [8].  
Therefore, we made some modifications in 
chromatographic conditions and have developed a 
HPLC method suitable for determination of acyclovir 
in plasma samples employing protein precipitation 
method for sample preparation. The advantage of the 
proposed method in comparison with other published 
papers is usage of 20 % perchloric acid for protein 
precipitation in order to achieve better separation of 
acyclovir peak from peaks of endogenous 
interferences compounds. This method enables 
simple and rapid isolation of acyclovir without using of 
internal standardization for the quantification and can 
increase the number of analysed samples in order to 
accomplish the pharmacokinetic study. 
 
 
Methods 
 
Materials 
Acyclovir working standard was supplied by 
Recordati, Industria Chimica E Farmaceutica S.O.A., 
Italy. Triethylamine, o-phosphoric acid and perchloric 
acid were obtained from Merck (Germany).  
 
Instrument and chromatographic conditions 
A series of parameters, including composition 
and pH of mobile phase, column packing, flow rate 
and detection wavelength, were tested with respect to 
the location and shape of the peak of acyclovir in the 
corresponding chromatograms. The final choice of the 
stationary phase giving satisfying resolution and run 
time was a reverse phase Hibar LiChrospher 100 
RP8, 250 x 4.6 mm I.D. (5 m, particle size), 
protected by a guard column LiChrospher RP8 4-4 
mm (5 m). A mobile phase consisting of 100 % water 
solution of 0.1 % (V/V) triethylamine with pH = 2.5 
adjusted with concentrated ortho-phosphoric acid 
delivered by a pump Perkin Elmer LC series 200 was 
found to give best results. The mobile phase was 
filtered and degassed with helium. A flow rate was 1.2 
ml/min. Chromatographic separations were performed 
at 25C. An ultraviolet diode array detector (Perkin 
Elmer LC 235 C) was used for detection and 255 nm 
was chosen as optimal for determination of acyclovir. 
The samples were introduced in the column using an 
autosampler Perkin Elmer LC ISS Series 200 and the 
injection volume was 120 µl. The chromatographic 
system was controlled by the software package 
Turbochrom Version 4.1. plus and UV-spectrometric 
data were produced by TurboScan Version 2.0. 
 
Preparation of standards 
Stock solution of 1000 µg/ml of acyclovir was 
prepared monthly in mixture of methanol and water in 
volume fractions 1:1 and stored at +4C. No change in 
stability over the period of 1 month was observed. The 
working solutions were prepared by diluting 
appropriate portions of this solution with distilled 
water. 
 
Sample preparation  
Human plasma samples were prepared by 
centrifuging (at 3000 rpm) of heparinized whole blood 
samples collected from healthy volunteers who later 
participated in a bioequivalence study of acyclovir.  
Prepared plasma samples were stored at -
20
o
C. Before the analysis blood plasma samples were 
thawed at 20C for about 10 minutes. A 0.5 ml volume 
of the sample was transferred into a vial and treated 
with 0.1 ml solution of 20 % (V/V) perchloric acid. The 
mixture is vortexed for 20 s and centrifugated for 10 
min at 10000 rpm. The supernatant was filtered using 
filter with pore size of 0.45 m and 120 l volume was 
injected into the HPLC system. 
 
Calibration curves 
Typical calibration curves were constructed 
with six blank plasma samples spiked with appropriate 
amounts of the standard solutions. The calibration 
range was 0.1-2.0 µg/ml of acyclovir. The standard 
samples were prepared according to the procedure as 
unknown samples. The calibration curves were 
obtained by plotting the peak height versus 
concentration of acyclovir in µg/ml. The regression 
equations were calculated by the least-squares 
method. 
 
Application of the method 
A total of 24 healthy male volunteers gave 
their written informed consent to participate in 
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bioequivalence study of acyclovir. The health 
condition of the volunteers was established on the 
basis of anamnesis data, physical examination, ECG, 
biochemical and hematological analyses. This study 
was reviewed and approved by the Ethical Committee 
of the Faculty of Medicine, St. Cyril and Methodius 
University (Skopje, Macedonia). The study was a 
open, single dose, randomized, balanced, two-way 
crossover with a one-week wash-out period. Two 
weeks before investigation volunteers did not receive 
any drugs. The subjects were administered a single 
400 mg oral dose of acyclovir. 
Plasma samples were obtained before the 
administration of the drug (0 time) and at 12 time 
points following a single 400 mg oral dose of 
acyclovir. Following collection, the samples were 
stored at -20 ºC. After thawing, 0.5 ml plasma was 
analyzed as described before. 
 
 
Results  
 
Method validation 
Under the chromatographic conditions 
described, acyclovir peak was well resolved. 
Endogenous plasma components did not give any 
interfering peaks. A typical chromatogram of diluent 
(a), standard solution of acyclovir (b) produced by the 
developed HPLC method is shown in Fig. 1. Retention 
time of acyclovir is 7.75 min. Chromatograms of blank 
plasma in comparison to spiked samples prepared 
using the method of standard addition are shown in 
Fig. 1 (c, d). 
 
 
Figure 1: Chromatograms of diluents (a), standard solution of 
acyclovir (b), blank plasma sample (c) and spiked plasma sample 
with acyclovir (d). 
 
Linearity of the method was tested in three 
different days at six concentration points ranged from 
0.1 to 2.0 µg/ml of acyclovir in plasma samples. 
Respective regression equation was: y = 9763.4· - 
24.321. The correlation coefficient was 0.9985.  
In one day and in 3 different days, spiked 
samples from each concentration used for 
construction of calibration curves were prepared in 
triplicate and analyzed by the proposed HPLC 
method. Then, the corresponding coefficients of 
variation were calculated. The intra- and inter-day 
variations of the method throughout the linear range of 
concentrations are shown in Table 1.  
 
Table 1. Intra-and inter-day precision and accuracy data. 
Acyclovir 
nominal 
concentration 
(gml
1
) 
Intra-day Inter-day 
Mean (n=3) 
observed 
concentration 
(gml
1
) 
Relative 
standard        
deviation 
(%) 
Mean (n=9) 
observed 
concentration 
(gml
1
) 
Relative 
standard        
deviation (%) 
Precision 
0.1 0.10 1.15 0.09 2.72 
0.2 0.21 4.62 0.21 4.46 
0.5 0.52 1.02 0.51 1.74 
0.9 0.89 3.19 0.87 3.11 
1.5 1.43 2.58 1.41 3.52 
2.0 2.08 8.37 1.99 6.88 
Accuracy  
Relative 
error (%) 
 
Relative error 
(%) 
0.3 
0.7 
1.2 
0.31 
0.74 
1.20 
3.33 
5.71 
0.0 
0.31 
0.68 
1.12 
3.33 
-2.86 
-6.66 
 
Intra- and inter-day accuracy was determined 
by measuring plasma quality control samples at low, 
middle and high concentration levels. An indication of 
accuracy was based on the calculation of the relative 
error of the mean observed concentration as 
compared to the nominal concentration. Accuracy 
data are presented in Table 1.  
The limit of quantification was defined as the 
lowest amount detectable with a precision of less than 
15 % (n=5) and an accuracy of 15 % (n = 5). The 
limit of quantification was found to be 0.1 µg/ml for 
plasma samples.  
Stability of acyclovir in plasma samples was 
investigated using spiked samples at two different 
concentration levels prepared in duplicate. Spiked 
samples were analysed after different storage 
conditions: immediately, after staying in an 
autosampler for 2, 12 and 24 hours, after one and two 
freeze/thaw cycles and after 1 month stored at –20 
C. The results from this investigation show that 
acyclovir added to plasma samples is stable in the 
different storage conditions (relative errors were 
ranged from 1.15 % to 6.98 %).  
Ruggedness was performed on the second 
column of the same type by determining repeatability 
and accuracy analysing three series of quality control 
samples. From three determinations per concentration 
relative standard deviations were ranged from 0.58 % 
to 4.49 % and relative errors were ranged from -1.57 
% to 4.0 % which means that this HPLC method for 
determination of acyclovir in spiked human plasma 
samples is rugged. 
On the other hand, the method in this report 
has sufficient sensitivity and reproducibility to permit 
the pharmacokinetic studies. The developed HPLC 
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method was used for analysis of plasma samples from 
healthy volunteers after oral administration of 400 mg 
acyclovir. Typical chromatograms of plasma extracts 
of a volunteer after administration of 400 mg acyclovir 
are shown in Fig. 2. Chromatograms showed no 
interfering peak at the acyclovir peak position.  
 
 
Figure 2: Chromatograms of plasma samples from healthy 
volunteers dosed with 400 mg acyclovir 0.33 h, 0.66 h, 1 h, 1.33 h, 
1.66 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h and 24 h post dose respectively 
(from the first point sampling 0.33 h followed by the rest point 
samplings). 
 
 
Pharmacokinetic study of acyclovir 
 
 The described HPLC method was 
successfully applied in a bioequivalence study of 
acyclovir formulation on 24 healthy volunteers. Fig. 3 
presents the mean plasma acyclovir concentration-
time profiles after oral administration of 2x200 mg test 
acyclovir formulation or 2x200 mg acyclovir (a 
reference formulation of acyclovir - Zovirax). As can 
be seen from Fig. 3, the character of both curves is 
practically the same. Following oral administration of 
acyclovir and Zovirax tablets, maximum plasma 
concentration of 452 and 432 ng/ml were achieved 
after 1.39 h and 1.40 h, respectively. 
 
 
Figure 3: Plasma concentration – time curve of Acyclovir. 
The corresponding pharmacokinetic 
parameters (mean ± SD) obtained by 24 independed 
analyses and the relative bioavailability of the generic 
acyclovir tablet are presented in Table 2.  
 
Table 2. Mean pharmacokinetic parameters of acyclovir after a 
single 400 mg oral dose 
Pharmacokinetic parameter Acyclovir tablet Zovirax tablet 
Cmax (ng ml
-1
) 
tmax (h) 
t1/2 (h) 
AUC0-t (ng h ml
-1
) 
AUC0-∞ (ng h ml
-1
) 
Fr 
452  110 
1.39  0.55 
3.59  1.1 
1782  600 
2439  623 
100.6  5.5 
432  108 
1.40  0.38 
3.87  1.54 
1687  627 
2485  955 
- 
Cmax – mean plasma acyclovir concentration; tmax – time to achieve the peak concentration 
t1/2 – elimination half-life; AUC0-t – area under the plasma concentration-time curve from 0 
to t; AUC0-∞ - area under the plasma concentration-time curve from 0 to infinity; Fr – 
relative bioavailability defined as AUCacyclovir/AUCZovirax 
 
 
Discussion 
 
In our laboratory a series of studies were 
conducted in order to develop a convenient and easy-
to-use method for quantitative analysis of acyclovir in 
human plasma. Several HPLC method variables with 
respect to their effect on the separation of acyclovir 
from the matrix were investigated.  
In our extensive preliminary experiments a 
series of aqueous mobile phases containing buffer 
solutions with different pH values in combination with 
different modifiers including acetonitrile, methanol and 
triethylamine with different volume fractions were 
tested. The results were most satisfactory when 
mobile phase consisted of 100 % water solution of 0.1 
% (V/V) triethylamine with pH=2.5.  
A set of column packing including C8 and C18 
with different lengths and particle sizes were tested 
and the LHibar LiChrospher 100 RP 8 packing 
showed best separation. Among several flow-rates 
tested (0.8-2 ml/min) the rate of 1.2 ml/min was the 
best with respect to location and resolution of the 
peaks of acyclovir from the interfering peaks. The 
elution was monitored in the whole UV region and the 
wavelength of 255 nm exhibited the best detection. 
Results of method validation for intra-day 
precision show that RSDs ranged from 1.02 to 8.37 % 
and for inter-day precision, RSDs ranged from 1.74 to 
6.88 %.  These data indicate a considerable degree of 
precision and reproducibility for the method both 
during one analytical run and between different runs. 
On the other hand, the values for relative 
errors at all three concentrations studied for plasma 
samples are less than 6.66 % and it is obvious that 
the method is remarkably accurate which ensures 
obtaining of reliable results. 
The present method was applied in 
bioequivalence study of two preparations containing 
acyclovir. The statistical analysis of pharmacokinetic 
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parameters: Cmax, tmax, t1/2, AUC0-t and AUC0-∞ with the 
two-way analysis of variance, single observation 
(ANOVA) shows that there are no differences 
between the compared drugs. The relative 
bioavailability of the investigated formulation, i.e., the 
acyclovir tablet (manufactured by Jaka 80 Company) 
was 100.6 % of that obtained for the proprietary 
product, Zovirax. Based on these results, it may be 
concluded that acyclovir tablets are bioequivalent to 
Zovirax tablets. 
In conclusion, the developed HPLC method 
employing protein precipitation is simple and 
convenient for the determination of acyclovir in 
plasma samples. Acyclovir has been successfully 
separated. The proposed method is simply, rapid and 
provides efficient clean up of the complex biological 
matrix. The validation data demonstrate good 
precision and accuracy, which proves the reliability of 
the proposed method. Finally, the method has been 
implemented to pharmacokinetic study of acyclovir.  
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